The market is grossly mispricing heavily defeased CMBS, although it is true that the illiquidity and weak technicals make it difficult to trumpet relative value in the current market, Barclays Capital analysts said in a recent report.

According to the analysts, even those investors who are now sidelined should still look at the value implications of defeased paper, while awaiting a better value-investing scenario.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.